Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMPH Stock Forecast 2026-2027
$26.07
Current Price
$1.21B
Market Cap
Buy 3
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to AMPH Price Targets
+45.8%
To High Target of $38.00
+15.1%
To Median Target of $30.00
-4.1%
To Low Target of $25.00
AMPH Price Momentum
-11.3%
1 Week Change
-2.0%
1 Month Change
-27.0%
1 Year Change
-2.7%
Year-to-Date Change
-30.8%
From 52W High of $37.66
+27.9%
From 52W Low of $20.39
📊 TOP ANALYST CALLS
Did AMPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amphastar is one of their latest high-conviction picks.
Latest AMPH Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, AMPH has a neutral consensus with a median price target of $30.00 (ranging from $25.00 to $38.00). The overall analyst rating is Buy (7.4/10). Currently trading at $26.07, the median forecast implies a 15.1% upside. This outlook is supported by 3 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by David Amsellem at Piper Sandler, suggesting a 4.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMPH Analyst Ratings
3
Buy
4
Hold
0
Sell
AMPH Price Target Range
Low
$25.00
Average
$30.00
High
$38.00
Current: $26.07
Latest AMPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | Barclays | Glen Santangelo | Equal-Weight | Initiates | $30.00 |
| Nov 7, 2025 | Needham | Serge Belanger | Buy | Maintains | $34.00 |
| Oct 22, 2025 | Needham | Serge Belanger | Buy | Reiterates | $36.00 |
| Aug 26, 2025 | B of A Securities | Jason Gerberry | Neutral | Maintains | $32.00 |
| Aug 12, 2025 | Needham | Serge Belanger | Buy | Upgrade | $36.00 |
| Aug 8, 2025 | Piper Sandler | David Amsellem | Neutral | Maintains | $25.00 |
| May 12, 2025 | JP Morgan | Ekaterina Knyazkova | Neutral | Downgrade | $30.00 |
| May 8, 2025 | Wells Fargo | Cerena Chen | Overweight | Maintains | $35.00 |
| Apr 10, 2025 | Needham | Serge Belanger | Hold | Reiterates | $N/A |
| Mar 21, 2025 | Piper Sandler | David Amsellem | Neutral | Maintains | $32.00 |
| Feb 4, 2025 | Piper Sandler | David Amsellem | Neutral | Downgrade | $36.00 |
| Nov 22, 2024 | Wells Fargo | Joe Quatrochi | Overweight | Initiates | $55.00 |
| Aug 8, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $66.00 |
| Aug 8, 2024 | Needham | Serge Belanger | Hold | Reiterates | $N/A |
| Jun 27, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $71.00 |
| May 22, 2024 | Needham | Serge Belanger | Hold | Reiterates | $N/A |
| May 9, 2024 | Needham | Serge Belanger | Hold | Reiterates | $N/A |
| Apr 10, 2024 | Needham | Serge Belanger | Hold | Reiterates | $N/A |
| Mar 5, 2024 | JP Morgan | Ekaterina Knyazkova | Overweight | Initiates | $60.00 |
| Nov 17, 2023 | B of A Securities | Jason Gerberry | Neutral | Initiates | $63.00 |
Amphastar Pharmaceuticals Inc. (AMPH) Competitors
The following stocks are similar to Amphastar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amphastar Pharmaceuticals Inc. (AMPH) Financial Data
Amphastar Pharmaceuticals Inc. has a market capitalization of $1.21B with a P/E ratio of 11.5x. The company generates $723.31M in trailing twelve-month revenue with a 15.4% profit margin.
Revenue growth is +0.3% quarter-over-quarter, while maintaining an operating margin of +25.2% and return on equity of +14.8%.
Valuation Metrics
Market Cap
$1.21B
Enterprise Value
$1.66B
P/E Ratio
11.5x
PEG Ratio
-0.2x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+0.3%
Gross Margin
+51.4%
Operating Margin
+25.2%
Net Margin
+15.4%
EPS Growth
-57.1%
Financial Health
Cash/Price Ratio
+23.1%
Current Ratio
3.1x
Debt/Equity
84.6x
ROE
+14.8%
ROA
+6.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amphastar Pharmaceuticals Inc. (AMPH) Business Model
About Amphastar Pharmaceuticals Inc.
What They Do
Specialty pharmaceutical company offering innovative medications.
Business Model
Amphastar Pharmaceuticals develops, manufactures, and markets both generic and proprietary injectable, inhalation, and intranasal products. The company generates revenue by providing cost-effective alternatives to high-cost brand-name drugs, particularly in critical therapeutic areas such as endocrinology and pain management.
Additional Information
Headquartered in Rancho Cucamonga, California, Amphastar operates domestically and internationally, adhering to strict quality control and regulatory standards. The company is essential in addressing medication shortages and enhancing patient care through its diverse product portfolio.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,028
CEO
Dr. Yongfeng Zhang Ph.D.
Country
United States
IPO Year
2014
Website
www.amphastar.comAmphastar Pharmaceuticals Inc. (AMPH) Latest News & Analysis
Latest News
Quick Summary
Amphastar Pharmaceuticals, Inc. (AMPH) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting company updates and strategic initiatives.
Why It Matters
Amphastar's presentation at a major healthcare conference can indicate strategic direction, potential partnerships, and product updates, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Amphastar Pharmaceuticals (NASDAQ: AMPH) has signed an exclusive license agreement with Nanjing Hanxin for the development of AMP-110, a synthetic ACTH analog for inflammatory and autoimmune conditions.
Why It Matters
The agreement enhances Amphastar's product portfolio, potentially increasing revenue streams by targeting broader inflammatory and autoimmune markets, which may boost investor confidence and stock valuation.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Amphastar Pharmaceuticals’ CEO Jack Zhang and CFO Bill Peters will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, at 2:15 pm PT.
Why It Matters
Amphastar Pharmaceuticals' presentation at a major healthcare conference could influence investor sentiment and stock performance, showcasing its strategic direction and financial health.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Floyd Petersen sold 16,679 shares of Amphastar in November for over $441,000, while still holding approximately $2 million in shares.
Why It Matters
Floyd Petersen's exercise and sale of shares signals confidence in Amphastar's performance, potentially influencing investor sentiment and stock price.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced FDA approval for its teriparatide injection, confirming it is bioequivalent to Eli Lilly's FORTEO®.
Why It Matters
Amphastar's FDA approval for teriparatide boosts its market position, offering a competitive alternative to Eli Lilly's FORTEO, potentially increasing revenue and market share.
Source: Accesswire
Market Sentiment:
Neutral
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
1 month ago
Quick Summary
Amphastar Pharmaceuticals (NASDAQ:AMPH) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2025, at 2:00 pm ET. Access via their website.
Why It Matters
The participation of Amphastar's executives in a prominent healthcare conference may signal strategic insights or upcoming developments, influencing investor sentiment and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About AMPH Stock
What is Amphastar Pharmaceuticals Inc.'s (AMPH) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Amphastar Pharmaceuticals Inc. (AMPH) has a median price target of $30.00. The highest price target is $38.00 and the lowest is $25.00.
Is AMPH stock a good investment in 2026?
According to current analyst ratings, AMPH has 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMPH stock?
Wall Street analysts predict AMPH stock could reach $30.00 in the next 12 months. This represents a 15.1% increase from the current price of $26.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amphastar Pharmaceuticals Inc.'s business model?
Amphastar Pharmaceuticals develops, manufactures, and markets both generic and proprietary injectable, inhalation, and intranasal products. The company generates revenue by providing cost-effective alternatives to high-cost brand-name drugs, particularly in critical therapeutic areas such as endocrinology and pain management.
What is the highest forecasted price for AMPH Amphastar Pharmaceuticals Inc.?
The highest price target for AMPH is $38.00 from at , which represents a 45.8% increase from the current price of $26.07.
What is the lowest forecasted price for AMPH Amphastar Pharmaceuticals Inc.?
The lowest price target for AMPH is $25.00 from David Amsellem at Piper Sandler, which represents a -4.1% decrease from the current price of $26.07.
What is the overall AMPH consensus from analysts for Amphastar Pharmaceuticals Inc.?
The overall analyst consensus for AMPH is neutral. Out of 12 Wall Street analysts, 3 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are AMPH stock price projections?
Stock price projections, including those for Amphastar Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 12:52 AM UTC